Chemical: Drug
tenoxicam

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

List of all variant annotations for tenoxicam

Gene ? Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available No VIP available VA CYP2C9 *1 N/A N/A N/A
No VIP available No VIP available VA CYP2C9 *2 N/A N/A N/A
No VIP available No VIP available VA CYP2C9 *3 N/A N/A N/A
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Generic Names
  • Tenoxicamum [INN-Latin]
Trade Names
  • Apo-Tenoxicam
  • Novo-Tenoxicam
  • Tilcotil
Brand Mixture Names

PharmGKB Accession Id

PA131890625

Type(s):

Drug

Description

Tenoxicam, an antiinflammatory agent with analgesic and antipyretic properties, is used to treat osteoarthritis and control acute pain.

Source: Drug Bank

Indication

For the treatment of rheumatoid arthritis, osteoarthritis, backache, and pain.

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

The antiinflammatory effects of tenoxicam may result from the inhibition of the enzyme cycooxygenase and the subsequent peripheral inhibition of prostaglandin synthesis. As prostaglandins sensitize pain receptors, their inhibition accounts for the peripheral analgesic effects of tenoxicam. Antipyresis may occur by central action on the hypothalamus, resulting in peripheral dilation, increased cutaneous blood flow, and subsequent heat loss.

Source: Drug Bank

Pharmacology

Tenoxicam, an antiinflammatory agent with analgesic and antipyretic properties, is used to treat osteoarthritis and control acute pain.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

Tenoxicam is metabolized in the liver to several pharmacologically inactive metabolites (mainly 5'-hydroxy-tenoxicam).

Source: Drug Bank

Protein Binding

99%

Source: Drug Bank

Absorption

Oral absorption of tenoxicam is rapid and complete (absolute bioavailability 100%).

Source: Drug Bank

Half-Life

72 hours (range 59 to 74 hours)

Source: Drug Bank

Chemical Properties

Chemical Formula

C13H11N3O4S2

Source: Drug Bank

Isomeric SMILES

CN1C(=C(c2c(ccs2)S1(=O)=O)O)C(=O)Nc3ccccn3

Source: OpenEye

Canonical SMILES

CN1\C(=C(/O)NC2=CC=CC=N2)C(=O)C2=C(C=CS2)S1(=O)=O

Source: Drug Bank

Average Molecular Weight

337.374

Source: Drug Bank

Monoisotopic Molecular Weight

337.019097235

Source: Drug Bank

SMILES

CN1\C(=C(/O)NC2=CC=CC=N2)C(=O)C2=C(C=CS2)S1(=O)=O

Source: Drug Bank

InChI String

InChI=1S/C13H11N3O4S2/c1-16-10(13(18)15-9-4-2-3-6-14-9)11(17)12-8(5-7-21-12)22(16,19)20/h2-7,18H,1H3,(H,14,15)/b13-10-

Source: Drug Bank

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

Drug Targets

Gene Description
PTGS1 (source: Drug Bank)
PTGS2 (source: Drug Bank)

Drug Interactions

Interaction Description
cyclosporine - tenoxicam Monitor for nephrotoxicity (source: Drug Bank)
cyclosporine - tenoxicam Monitor for nephrotoxicity (source: Drug Bank)
tenoxicam - acenocoumarol The NSAID increases the anticoagulant effect (source: Drug Bank)
tenoxicam - acenocoumarol The NSAID, tenoxicam, may increase the anticoagulant effect of acenocoumarol. (source: Drug Bank)
tenoxicam - alendronate Increased risk of gastric toxicity (source: Drug Bank)
tenoxicam - alendronate Increased risk of gastric toxicity (source: Drug Bank)
tenoxicam - anisindione The NSAID, tenoxicam, may increase the anticoagulant effect of anisindione. (source: Drug Bank)
tenoxicam - chlorthalidone Tenoxicam may antagonize the blood pressure lowering effect of Chlorthalidone. Monitor for changes in the therapeutic effect of Chlorthalidone if Tenoxicam is initiated, discontinued or dose changed. (source: Drug Bank)
tenoxicam - cholestyramine Cholestyramine may decrease the serum concentration of Tenoxicam by increasing clearance. Monitor for changes in Tenoxicam therapeutic and adverse effects if Cholestyramine is initiated, discontinued or dose changed. (source: Drug Bank)
tenoxicam - cyclosporine Monitor for nephrotoxicity (source: Drug Bank)
tenoxicam - cyclosporine Monitor for nephrotoxicity (source: Drug Bank)
tenoxicam - dicumarol The NSAID increases the anticoagulant effect (source: Drug Bank)
tenoxicam - dicumarol The NSAID, tenoxicam, may increase the anticoagulant effect of dicumarol. (source: Drug Bank)
tenoxicam - hydrochlorothiazide Tenoxicam may antagonize the blood pressure lowering effect of Hydrochlorothiazide. Monitor for changes in the therapeutic effect of Hydrochlorothiazide if Tenoxicam is initiated, discontinued or dose changed. (source: Drug Bank)
tenoxicam - lithium Tenoxicam may increase the serum concentration of Lithium. A dose adjustment of Lithium may be required. Monitor for changes in Lithium therapeutic and adverse effects if Tenoxicam is initiated, discontinued or dose changed. (source: Drug Bank)
tenoxicam - methotrexate Tenoxicam may increase the serum concentration of Methotrexate by reducing renal tubular secretion of Methotrexate. Monitor for changes in Methotrexate therapeutic and adverse effects if Tenoxicam is initiated, discontinued or dose changed. (source: Drug Bank)
tenoxicam - metolazone Tenoxicam may antagonize the blood pressure lowering effect of Metolazone. Monitor for changes in the therapeutic effect of Metolazone if Tenoxicam is initiated, discontinued or dose changed. (source: Drug Bank)
tenoxicam - warfarin The NSAID increases the anticoagulant effect (source: Drug Bank)
tenoxicam - warfarin The NSAID, tenoxicam, may increase the anticoagulant effect of warfarin. (source: Drug Bank)
No related diseases are available

Publications related to tenoxicam: 3

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics of acetylsalicylic acid and other nonsteroidal anti-inflammatory agents: clinical implications. European journal of clinical pharmacology. 2013. Yiannakopoulou Eugenia. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Pharmacogenetic relevance of the CYP2C9*3 allele in a tenoxicam bioequivalence study performed on Spaniards. Pharmacological research : the official journal of the Italian Pharmacological Society. 2009. Peiró A M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians. Clinical pharmacology and therapeutics. 2004. Vianna-Jorge Rosane, et al. PubMed

LinkOuts

DrugBank:
DB00469
KEGG Drug:
D01767
PubChem Compound:
5312154
PubChem Substance:
183540
46507303
Drugs Product Database (DPD):
2231120
ChemSpider:
4471584
Therapeutic Targets Database:
DAP000736

Clinical Trials

These are trials that mention tenoxicam and are related to either pharmacogenetics or pharmacogenomics.

No trials loaded.

NURSA Datasets

provided by nursa.org

No NURSA datasets available.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, PubChem.